This page shows the latest Emma Walmsley news and features for those working in and with pharma, biotech and healthcare.
We believe that next generation vaccines will be crucial in the continued fight against COVID-19,” said Emma Walmsley, chief executive officer of GSK.
GSK’s CEO Emma Walmsley and R&D chief Hal Barron have led the company’s re-entry into oncology, having overseen a number of new additions to the oncology pipeline.
GlaxoSmithKline’s chief executive officer Emma Walmsley (pictured above) is ‘optimistic’ that a vaccine against COVID-19 will be widely available in 2021. ... Speaking at the third annual Helen Alexander Memorial Lecture – an online event of the
On a conference call last month, GSK CEO Emma Walmsley said that the company’s “first priority remains… to invest in R&D and future growth drivers”. ... Since the beginning of 2019, GSK and new CEO Walmsley have been trying to reverse that deal
GSK’s chief executive Emma Walmsley (pictured right) reiterated yesterday on a conference call that GSK’s “first priority remains… to invest in R&D and future growth drivers”, adding that
ago. GSK’s new CEO Emma Walmsley (pictured left) and new R&D chief Hal Barron have helmed the company’s re-entry into oncology, having overseen a number of new
More from news
Approximately 2 fully matching, plus 50 partially matching documents found.
It’s also great to see outside Merck that women are also progressing in other companies too – like Emma Walmsley at GSK – which gives women the inspiration that they too can
10. THEODORA HAROLD . Biotech leader. While big pharma is making some significant strides in having women as their top leaders (most notably GSK’s CEO Emma Walmsley), the biotech sector, particularly
If, as GlaxoSmithKline CEO Emma Walmsley said, talking about diversity to Business Insider UK, ‘‘You cannot be a modern employer in an industry that should be future facing and modernising arguably
29. Emma Walmsley, GSK CEO. Emma Walmsley is the first-ever woman leader of a big pharma company, having taken on the CEO role at GlaxoSmithKline in April 2017. ... Since then, Walmsley has very definitely put her own stamp on the firm, making major
Emma Walmsley, CEO of GSK, said: “We will use cash for business development purposes, with M&A obviously dependent on the right kind of return profile.”.
More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.
Emma Walmsley, GSK's chief executive officer designate, said: “Luke brings a combination of excellent R&D insight and a strong track record of commercial execution.
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
Triducive are a strategic healthcare consultancy who produce communications that have practical, dynamic application that encourage behaviour change because of the...